by Jordan Sava
Impressive efficacy data and consistent safety data continue to be seen with mirvetuximab soravtansine for the treatment of patients with platinum-resistant ovarian cancer, according to data from the confirmatory MIRASOL trial.
Mirvetuximab sorvtansine-gynx (Elahere) demonstrated statistically significant
by Leah Lawrence
Early-phase trials testing the safety and efficacy of PARP inhibition plus ataxia telangiectasia- and Rad3-related kinase (ATR) inhibition in biomarker-selected patients show intriguing results, researchers reported at the AACR Annual Meeting 2023.
“ATR inhibition prevents recovery from … Read more
There are currently three antibody drug conjugates (ADC) targeting B7-H4 being tested in clinical trials: AZD8205 (NCT05123482), SGN-B7-H4V (NCT05194072) and XMT-1660 (NCT05377996). You can use Clearity’s clinical trial finder to find more information about these trials.
As part of the … Read more
Reviewed by Emily Henderson, B.Sc
Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare … Read more
by Nichole Tucker
The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.
The investigational combination of lifirafenib (BGB-283) and mirdametinib (PD-0325901) has shown a favorable safety profile, as well … Read more
by Nichole Tucker
The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting … Read more
by Charles Bankhead
TAMPA, Fla. — About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to the combination of CDK4/6 inhibitor ribociclib (Kisqali) and letrozole, a small single-arm trial showed.
Overall, 23% of 48 … Read more
by Jessica Nye, PhD
Patients with platinum-resistant epithelial ovarian cancer may have better overall survival (OS) if they enroll on a clinical trial than if they receive standard care, according to study results presented at the 2023 SGO Annual Meeting … Read more
by Devin McLaughlin
Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers observed favorable surgical outcomes — even … Read more
by Jason Harris
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1… Read more
by Hayley Virgil
Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.
Combining hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery
by University of Pittsburgh
Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC researchers that may help explain why ovarian cancer patients respond … Read more
by Justin Jackson
An international team led by researchers from MacCallum Cancer Center in Melbourne, Australia, examined 391 tumor tissues from about 270 multisite autopsy samples collected from 15 individuals with end-stage high-grade serous ovarian cancer (HGSC). All of the … Read more
by Jennifer Byrne
Patient withdrawal from cancer clinical trials can result in systematic bias, insufficiently powered studies and a loss of valuable scientific knowledge, according to a study in JAMA Network Open.
Although increased attention has been paid to … Read more
by Jordyn Sava
With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.
The combination of avutometinib (VS-6766) with defactinib (VS-6063), as … Read more
by Jennifer Southall
Women who underwent surgery for gynecologic cancers experienced decreased symptoms of anxiety and pain with the use of acupressure before surgery and acupuncture during surgery, according to study results published in Cancer.
Further investigation is needed … Read more
by Caroline Seymour
Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.
Treatment with the folate receptor
by Anita T. Shaffer
Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.… Read more
by Ryan Scott
A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.
A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo)
A genetic test developed in a study at the University of Helsinki and Helsinki University Hospital identifies ovarian cancer patients who benefit from PARP inhibitors, a treatment option.
Since the therapy is associated with potential serious side-effects, it is important … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
